Mainz Biomed (NASDAQ:MYNZ) Shares Up 10.6% – Here’s What Happened

Mainz Biomed NV (NASDAQ:MYNZ)’s stock price traded up 10.6% during trading on Tuesday . The company traded as high as $1.58 and last traded at $1.57. 1,364,910 shares changed hands during trading, an increase of 267% from the average session volume of 371,589 shares. The stock had previously closed at $1.42.

Mainz Biomed Trading Up 8.1%

The company has a market cap of $14.50 million, a P/E ratio of -0.02 and a beta of 0.31. The firm’s 50 day moving average is $1.35 and its two-hundred day moving average is $1.25. The company has a quick ratio of 0.43, a current ratio of 0.52 and a debt-to-equity ratio of 0.44.

Institutional Investors Weigh In On Mainz Biomed

A number of institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC increased its stake in shares of Mainz Biomed by 45.0% in the second quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock valued at $402,000 after buying an additional 88,400 shares during the period. Cerity Partners LLC acquired a new position in shares of Mainz Biomed in the fourth quarter worth approximately $183,000. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Mainz Biomed by 200.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock valued at $34,000 after acquiring an additional 20,000 shares during the last quarter.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.